« Back
Home /
Brincidofovir

Brincidofovir

Item no.	HY-14532-100mg
Manufacturer	MedChem Express
CASRN	444805-28-1
Amount	100 mg
Quantity options	100 mg 10 mM x 1 mL 10 mg 1 ea 1 mg 25 mg 2 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitor
Specific against	other
Purity	99.00
Formula	C27H52N3O7P
Citations	[1]Hiwarkar P, et al. Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant. Blood. 2017;129(14):2033-2037. [2]Detweiler CJ, et al. Brincidofovir (CMX001) Toxicity Associated With Epithelial Apoptosis and Crypt Drop Out in a Hematopoietic Cell Transplant Patient: Challenges in Distinguishing Drug Toxicity From GVHD. J Pediatr Hematol Oncol. 2018;40(6):e364-e368. [3]Zaitseva M, McCullough KT, Cruz S, et al. Postchallenge administration of brincidofovir protects healthy and immune-deficient mice reconstituted with limited numbers of T cells from lethal challenge with IHD-J-Luc vaccinia virus. J Virol. 2015;89(6):3295-3307. [4]Scott A Foster , et al. The Role of Brincidofovir in Preparation for a Potential Smallpox Outbreak. Viruses. 2017 Oct 30;9(11):320.
Smiles	NC1=NC(N(C[C@@H](CO)OCP(O)(OCCCOCCCCCCCCCCCCCCCC)=O)C=C1)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	CMX001, HDP-CDV
Shipping condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-anti-virus
Manufacturer - Targets	CMV; HSV; Orthopoxvirus
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	561.69
Product Description	Brincidofovir (CMX001), the lipid-conjugated prodrug of Cidofovir (HY-17438), is an orally available, long-acting antiviral. Brincidofovir shows activity against a broad spectrum of DNA viruses including cytomegalovirus (CMV), adenovirus (ADV), varicella zoster virus, herpes simplex virus, polyomaviruses, papillomaviruses, poxviruses, and mixed double-stranded DNA virus infections. Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo.[1][2][3][4].
Manufacturer - Research Area	Infection
Solubility	DMSO : 1 mg/mL (adjust pH to 8 with NaOH; heat to 50°C)
Manufacturer - Pathway	Anti-infection
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-14532-100mg-safety-datasheet.pdf